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Purpose: Obesity is associated with an increased risk of development and recurrence of
colorectal cancer. However, the role of obesity in advanced colorectal cancer (ACC) patients
is unknown. We investigated the effect of body mass index (BMI) on overall survival (OS) in
ACC patients receiving systemic treatment in two large phase III studies (CAIRO and
CAIRO2).
Patients and methods: Treatment data were obtained and analysed from 796 ACC patients
who were treated with chemotherapy in the CAIRO study, and from 730 ACC patients
who were treated with chemotherapy plus targeted therapy in the CAIRO2 study. Baseline
height and weight were used to assign patients to one of the following BMI categories: A
(<18.5 kg/m2), B (18.5–24.9 kg/m2), C (25.0–29.9 kg/m2) and D (P30.0 kg/m2).
Results: In 796 patients of the CAIRO study a high BMI was associated with better median
OS (8.0, 14.9, 18.4 and 19.5 months for BMI categories A, B, C, and D, respectively;
P = 0.001), and was an independent prognostic factor for OS in a multivariate analysis.
BMI was not associated with OS in 730 patients who participated in the CAIRO2 study,
although a trend was observed.
Conclusions: These results show that BMI is an independent prognostic factor for survival in
patients receiving chemotherapy, but not in patients receiving chemotherapy and targeted
therapy. The possible decreased efficacy of bevacizumab in obese patients may explain this
discrepant result. The role of BMI in patients receiving targeted therapy should be further
tested.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.t of Medical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101,
1 24 3610353; fax: +31 24 3540788.
J.A. Punt).
 the Elsevier OA license.
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 2 5 6 0 –2 5 6 7 25611. Introduction kilograms) divided by height squared (in meters). PatientsObesity is associated with serious comorbidities, and its prev-
alence is increasing worldwide.1 Increased body mass index
(BMI) is a risk factor for the development of several types of
cancer, including colorectal cancer.2,3 Furthermore, several
studies have shown an association between obesity and colon
cancer recurrence and/or colon cancer specific mortality.4–7
However, results are ambiguous and may differ per class of
obesity and gender. For example, in a study among patients
receiving adjuvant chemotherapy for colon cancer, very obese
patients (BMI > 35 kg/m2) had a statistically significant in-
crease of 27% in cancer recurrence or death due to colon can-
cer compared to normal weight patients.5 Also in patients
with stage II or III rectal cancer, obese men were more likely
to have local recurrence.8 However, Meyerhart et al. found
that in patients with stage III colon cancer, BMI was not asso-
ciated with an increased risk of cancer recurrence and death.9
The mechanisms by which obesity induces or promotes
tumourigenesis vary by cancer site and may include insulin
resistance, bioavailability of endogenous sex steroids, and
localised inflammation.10 In obese patients receiving chemo-
therapy pathophysiological modifications may affect parame-
ters, such as volume distribution and drug clearance.11
Whether these mechanisms also influence survival in the ad-
vanced tumour stage is unknown. The role of obesity in pa-
tients with advanced colorectal cancer (ACC) has not been
established. Therefore, we examined the influence of BMI on
outcome in ACC patients participating in two large randomised
phase III studies.
2. Patients and methods
2.1. Study population
For this analysis prospectively collected data were obtained
from ACC patients participating in the CAIRO and CAIRO2 study.
Both studies were performed by the Dutch Colorectal Cancer
Group (DCCG). The CAIRO study is a randomised phase III study
with 820 patients in which the sequential versus the combined
use of capecitabine, irinotecan and oxaliplatin was investigated
(ClinicalTrials.gov NCT00312000).12,13 Patients were randomised
to receive either first-line treatment with capecitabine, second-
line irinotecan and third-line capecitabine plus oxaliplatin
(sequential treatment) or first-line treatment capecitabine plus
irinotecan and second-line capecitabine plus oxaliplatin (com-
bination treatment). In the CAIRO2 study 755 patients were ran-
domly assigned between first line treatment with capecitabine,
oxaliplatin and bevacizumab with (arm B) or without (arm A)
cetuximab (ClinicalTrials.gov NCT00208546).14,15 In both stud-
ies, assessment of tumour response was scheduled every 3 cy-
cles (9 weeks) according to Response Evaluation Criteria in
Solid Tumours (RECIST).16 Details of eligibility criteria and re-
sults have been reported elsewhere.12,14
2.2. BMI
Patient’s length and body weight were measured by the local
investigator at baseline. BMI was calculated as weight (inwere assigned to one of the following BMI categories: A
(<18.5 kg/m2, underweight), B (18.5–24.9 kg/m2, normal
weight), C (25–29.9 kg/m2, overweight) and D (P30 kg/m2,
obese), according to international guidelines.17 For each of
the different BMI groups the incidence of grades 3–4 toxicities
according to the National Cancer Institute Common Toxicity
Criteria version 2.0 (CAIRO) and version 3.0 (CAIRO2) and pro-
gression-free survival (PFS) in first line treatment, and overall
survival (OS) were analysed. PFS was defined as the interval
from randomisation to first documented progression, death
or last follow-up, whichever came first. Overall survival (OS)
was defined as the interval from randomisation to death or
last follow-up. To assess the influence of dose capping in
obese patients, patients with a body surface area (BSA) of
P2.10 m2 who were dosed according to their actual body
weight and height and patients who were given a maximum
dose (a capping dose of chemotherapy based on a BSA of
2.00 m2) were analysed separately for toxicity.
2.3. Statistical evaluation
Differences between patient characteristics among the four
BMI categories were calculated using v2 test for categorical
variables and the Kruskal–Wallis test for numerical variables.
We also used v2 and Kruskal–Wallis test to analyse differences
in toxicity and median number of cycles, respectively. OS and
PFS curves were estimated using the Kaplan–Meier method
and compared with the log-rank test. In order to determine
whether BMI was an independent prognostic factor and to ad-
just for the impact of potential confounders, a Cox propor-
tional hazard model was used including treatment arm,
gender, WHO performance status, serum LDH level, leuco-
cytes, and number of metastatic sites. Survivors were cen-
sored at the date of last follow up. SAS version 8.2 was used
for statistical analysis. All tests were two-sided, and P values
of less than 0.05 were considered as statistically significant.
3. Results
3.1. BMI baseline characteristics
The distribution over the four different BMI categories was
comparable between the two study populations and was rep-
resentative for the general Dutch population.18 The study
population of the CAIRO2 study was comparable to the CAIRO
study population, except for age and performance status,
since patients with a performance status of 2 were excluded
in the CAIRO2 study.
Seven out of the 803 eligible patients in the CAIRO study
were excluded because they never started with first line treat-
ment. Of the 796 patients who were eligible for analysis, 14
(2%) patients were assigned to BMI category A, 380 (48%) to
category B, 306 (38%) to category C and 96 (12%) to category
D. Overweight patients were slightly older compared to the
normal weight patients (P = 0.006). Baseline characteristics
of the patients were comparable between the different BMI
groups for gender, performance status (0–1 versus 2), LDH at
randomisation (normal versus abnormal), leucocytes (<10 ver-
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and number of metastatic sites (Table 1).
In the CAIRO2 study, 730 out of the 736 eligible patients
were included in this analysis; 6 patients were excluded be-
cause they never started with first line treatment and/or no
data on baseline height and weight were available. Twelve
(2%) patients were underweight, 359 (49%) had a normal
weight, 274 (37%) were overweight and 85 (12%) patients were
obese. Patient characteristics of the CAIRO2 study population
are shown in Table 2. Although the numbers in category A and
D are low, patients with low BMI were of younger age, more
likely to be female, and more often had a worse performance
status. Patients with high BMI more often had received adju-
vant chemotherapy. Other baseline characteristics were well
balanced between the different BMI categories.
3.2. BMI and outcome in CAIRO study
An increasing BMI was significantly associated with a better
median OS (8.0, 14.9, 18.4 and 19.5 months for BMI category
A, B, C and D, respectively; P = 0.001) (Table 3, Fig. 1). At the time
of analysis, 719 of the 796 eligible patients had died, 367 in the
sequential arm and 352 in the combination arm, the remainder
was censored at the last date of follow-up. There was no differ-
ence in PFS between four BMI categories (4.4, 6.2, 7.2 and
7.0 months for category A, B, C, and D, respectively; P = 0.153).Table 1 – Patient characteristics according to BMI in the CAIRO
Characteristic BMI category
A (<18.5)
n = 14 (2%)
B (18.5–24.9)
n = 380 (48%)
C (2
n =
Age
Median (years)
(Range)
61
(40–83)
62
(27–84)
65
(31
Sex
Male 6 (43%) 229 (60%) 206
Female 8 (57%) 151 (40%) 100
Treatment
Sequential 9 (64%) 195 (51%) 149
Combination 5 (36%) 185 (49%) 157
Performance status
0 6 (46%) 214 (56%) 205
1 6 (46%) 148 (39%) 90
2 1 (8%) 19 (5%) 12
LDH
Normal 7 (50%) 239 (63%) 198
Abnormal 7 (50%) 141 (37%) 108
Prior adjuvant chemotherapy
Yes 0 49 (13%) 41
No 14 (100%) 331 (87%) 265
Number of metastatic sites
1–2 6 (43%) 173 (46%) 129
>2 7 (50%) 204 (54%) 174
Unknown 1 (7%) 3 (<1%) 3 (<
Leucocytes
<10 (109/l) 10 (71%) 237 (62%) 184
P10 (109/l) 1 (7%) 85 (22%) 64
Unknown 3 (21%) 58 (15%) 58The median number of treatment cycles increased with
increasing BMI, although this was not significantly different
(P = 0.392). The percentage of patients that received all three
cytotoxic drugs, second line treatment, and third line treat-
ment was comparable between the four different groups. The
incidence of first line grade 3–4 toxicity did not differ between
the four BMI categories (P = 0.363). Furthermore, patients who
received a capping dose experienced an equivalent amount
of grades 3–4 toxicity compared to patients who did not receive
a capping dose (sequential arm 25% versus 30%, P = 0.708; com-
bination arm 60% versus 66%, P = 0.793).
A multivariate analysis including treatment arm, gender,
serum LDH, leucocytes, number of metastatic sites, and per-
formance status showed that BMI was an independent prog-
nostic factor for OS with a hazard ratio (HR) for death of
1.644 (95% CI 0.893–3.025; P = 0.110), 0.807 (95% CI 0.675–
0.963; P = 0.018) and 0.728 (95% CI 0.551–0.961; P = 0.025) for
BMI category A, C and D, respectively, compared to category
B (Table 5) HR for death was 0.42 (95% CI 0.24–0.75; P = 0.002)
for obese patients compared to underweight patients in a test
across categories.
3.3. BMI and outcome in CAIRO2 study
In the CAIRO2 study population, a total of 518 patients had
died, 249 in arm A and 269 in arm B. The remainder wasstudy cohort.
5.0–29.9)
306 (38%)
D (P30.0)
n = 96 (12%)
Total
n = 796
P value
<0.006
–82)
63
(34–78)
63
(27–84)
0.102
(67%) 62 (65%) 503 (63%)
(33%) 34 (35%) 293 (37%)
0.517
(49%) 44 (46%) 397 (50%)
(51%) 52 (54%) 399 (50%)
0.337
(67%) 69 (73%) 494 (62%)
(29%) 24 (26%) 268 (34%)
(4%) 1 (1%) 33 (4%)
0.415
(65%) 67 (70%) 511 (64%)
(35%) 29 (30%) 285 (36%)
0.052
(13%) 21 (22%) 111 (14%)
(87%) 75 (78%) 685 (86%)
0.833
(42%) 43 (45%) 351 (44%)
(57%) 50 (52%) 435 (55%)
1%) 3 (3%) 9 (1%)
0.580
(60%) 54 (56%) 485 (61%)
(21%) 16 (17%) 166 (21%)
(19%) 26 (27%) 45 (7%)
Table 2 – Patient characteristics according to BMI in the CAIRO2 study cohort.
Characteristic BMI category
A (<18.5)
n = 12 (2%)
B (18.5–24.9)II
n = 359 (49%)
C (25.0–29.9)
n = 274 (37%)
D (P30.0)
n = 85 (12%)
Total
n = 730
P value
Age 0.016
Median (years)
(Range)
57
(47–78)
61
(31–83)
63
(33–78)
66
(34–78)
62
(31–83)
Sex <0.001
Male 2 (17%) 198 (55%) 187 (68%) 48 (56%) 435 (60%)
Female 10 (83%) 161 (45%) 87 (32%) 37 (44%) 295 (40%)
Treatment 0.997
Arm A 6 (50%) 181 (50%) 136 (50%) 42 (49%) 365 (50%)
Arm B 6 (50%) 178 (50%) 138 (50%) 43 (51%) 365 (50%)
Performance status 0.003
0 4 (33%) 211 (59%) 192 (70%) 50 (59%) 457 (63%)
1 8 (67%) 148 (41%) 82 (30%) 35(41%) 272 (37%)
LDH 0.060
Normal 6 (50%) 184 (51%) 168 (62%) 46 (55%) 404 (56%)
Abnormal 6 (50%) 175 (49%) 103 (38%) 38(45%) 322(44%)
Prior adjuvant chemotherapy 0.010
Yes 2(17%) 37 (10%) 44 (16%) 20 (24%) 103 (14%)
No 10 (83%) 322 (90%) 230 (84%) 65 (76%) 627 (80%)
Number of metastatic sites 0.926
1 4 (33%) 127 (35%) 90 (33%) 30 (34%) 251 (34%)
>1 8 (67%) 232 (65%) 184 (67%) 55 (65%) 477 (66%)
Leucocytes 0.116
<10 (109/l) 6 (50%) 263 (73%) 212 (77%) 64 (75%) 545 (75%)
P10 (109/l) 6 (50%) 95 (26%) 60 (22%) 19 (25%) 180 (25%)
Unknown 0 1 (<1%) 2 (<1%) 0 5 (<1%)
Table 3 – Efficacy and toxicity results according to BMI in the CAIRO study cohort.
Outcome BMI category
A (<18.5) (n = 14) B (18.5–24.9) (n = 380) C (25.0–29.9) (n = 306) D (P30.0) (n = 96) P value
No. of treatment cycles
Median
Range
9
0–27
9
0–55
11
0–48
12
1–66
0.392
Patients that received all drugs
No.
Percentage
7
50%
16,9
44%
14,1
46%
49
51%
0.648
Patients that received subsequent treatment
Second line 9 (64%) 210 (55%) 183 (60%) 61 (64%) 0.256
Third line 3 (21%) 66 (17%) 64 (21%) 17 (18%) 0.678
Overall survival (months)
Median
95% CI
8.0
5.7–21.0
14.9
13.4–16.2
18.4
16.3–20.4
19.5
17.3–24.6
0.001
Progression-free survival after first treatment line (months)
Median
95% CI
4.4
2.5–8.7
6.2
5.9–6.5
7.2
6.7–8.2
7.0
5.5–8.3
0.153
Any grade 3 or 4 toxicity
Event
Percentage
4
29%
19,8
52%
16,2
53%
50
52%
0.363
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with median OS, although a trend for better OS was observedin higher BMI categories (16.6, 17.8, 21.0, and 21.4 months for
BMI category A, B, C, and D, respectively; P = 0.807) (Table 4,
Table 4 – Efficacy and toxicity results according to BMI in the CAIRO2 study cohort.
Outcome BMI category
A (<18.5) (n = 12) B (18.5–24.9) (n = 359) C (25.0–29.9) (n = 274) D (P30.0) (n = 85) P value
No. of treatment cycles
Median
Range
9.5
1–20
9.0
1–56
9.5
1–58
10.0
1–60
0.417
Patients that received subsequent treatment
Second line 8 (67%) 146 (41%) 137 (50%) 46 (54%) 0.017
Overall survival (months)
Median
95% CI
16.6
(14.1–24.7)
17.8
(16.2–20.2)
21.0
(18.8–22.2)
21.4
(15.1–25.4)
0.807
Progression-free survival (months)
Median
95% CI
10.1
7.8–11.4
9.7
8.7–10.7
9.7
8.7–10.8
9.5
7.5–12.2
0.528
Any grade 3 or 4 toxicity
Event
Percentage
10
83%
28.8
80%
21.6
79%
66
78%
0.924
Fig. 1 – Kaplan–Meier estimates of overall survival rates by BMI category in the CAIRO study cohort. BMI category: A <18.5 kg/
m2, B 18.5–24.9 kg/m2, C 25–29.9 kg/m2, D P30 kg/m2.
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dence of grades 3–4 toxicity were comparable among the four
BMI categories. Normal weight patients less often received
second line treatment compared with the other BMI catego-
ries. In a multivariate analysis including treatment arm, gen-
der, serum LDH, leucocytes, number of metastatic sites and
performance status, BMI was not associated with OS. HR for
death was 1.092 (95% CI 0.575–2.073; P = 0.788), 0.996 (95% CI
0.819–1.211; P = 0.965) and 0.992 (95% CI 0.740–1.331;
P = 0.959) for BMI category A, C and D, respectively, compared
to category B (Table 6).
4. Discussion
We observed that BMI was an independent prognostic factor
for OS in the study cohort of ACC patients treated with che-
motherapy. However, this finding was not confirmed in a sec-
ond cohort of ACC patients treated with chemotherapy plus
targeted therapy with comparable baseline characteristics
who participated in a subsequent study.In obese patients, hyperinsulinemia may increase the risk
of colorectal cancer by increased levels of unbound insulin-
like growth factor 1, which increases proliferation and metas-
tasis of cancer cells.19,20 Furthermore, adipose tissue-derived
hormones may play a role in tumourgenesis.10
Though obesity has also shown to contribute to cancer-
related mortality,7 a high BMI has been associated with a
favourable prognosis in various tumour types, including cer-
vical cancer,21 head and neck cancer, oesophageal cancer22
and clear cell renal cell carcinoma.23 However, these studies
concerned all tumour stages, and BMI was associated with
cofactors, such as age and tumour grading. It is assumed that
underweight cancer patients have a worse survival because
cachexia may be a reflection of advanced stage and an aggres-
sive type of tumour. However, in the CAIRO study, not only a
decreased OS was found in underweight patients compared
to normal weight patients, but also a better OS was found in
overweight and obese patients. Maybe obese patients have
better nutritional resources to withstand the devastating ef-
fect of cancer itself. Of note, no difference in known
Table 6 – Multivariate analysis CAIRO2 study cohort.
Hazard ratio (95% CI) P value
Gender
Male R
Female 1.067 (0.887–1.284) 0.489
Treatment
Arm A R
Arm B 1.137 (0.951–1.358) 0.158
Performance status
0 R
1 1.220 (1.010–1.474) 0.039
LDH
Normal R
Abnormal 1.448 (1.203–1.742) <0.0001
Leucocytes
10 (109/l) R
P10 (109/l) 1.318 (1.068–1.628) 0.010
Number of metastatic sites
1–2 R
>2 1.479 (1.201–1.820) <0.001
BMI
A 1.092 (0.575–2.073) 0.788
B R
C 0.996 (0.819–1.211) 0.965
D 0.992 (0.740–1.331) 0.959
Table 5 – Multivariate analysis CAIRO study cohort.
Hazard ratio (95% CI) P value
Gender
Male R
Female 0.795 (0.669–0.944) 0.009
Treatment
Sequential R
Combination 0.867 (0.747–1.006) 0.061
Performance status
0–1 R
2 2.212 (1.530–3.197) <0.001
LDH
Normal R
Abnormal 1.905 (1.605–2.261) <0.001
Leucocytes
10 (109/l) R
P10 (109/l) 1.367 (1.127–1.657) 0.002
Number of metastatic sites
1–2 R
>2 1.470 (1.244–1.738) <0.001
BMI
A 1.644 (0.893–3.025) 0.110
B R
C 0.807 (0.675–0.963) 0.018
D 0.728 (0.551–0.961) 0.025
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categories.
Several other hypotheses have been presented. In obese
patients pathophysiological modifications may affect param-
eters, such as volume distribution and drug clearance. There-
fore the efficacy and toxicity of chemotherapy may be altered
in obese patients. For example, the more lipophilic an agent,
the more likely the volume of distribution will be affected.11
Miya et al. reported that BMI was an independent prognostic
predictor of peak plasma concentrations of irinotecan.24
However, in our study the incidence of toxicities was compa-
rable between the obese and normal weight patients, and be-
tween the patients who had dose capping and those who
were dosed according to their actual body weight. This doesFig. 2 – Kaplan–Meier estimates of overall survival rates by BMI ca
m2, B 18.5–24.9 kg/m2, C 25–29.9 kg/m2, D P30 kg/m2.not support that a relative overdosing of obese patients of li-
pid insoluble drugs such as irinotecan might explain the dif-
ference in median OS.
BMI was not associated with OS in a multivariate analysis
in the study cohort of patients treated with chemotherapy
and targeted therapy, although a trend for better OS was ob-
served in higher BMI categories. Patient characteristics were
comparable in the two study cohorts. However, in the second
cohort, age and performance status were significantly differ-
ent among the four BMI categories, with patients in the high-
er BMI categories having a better performance status. The
differences in age are of a magnitude that is unlikely to be
clinically relevant. Possible potential confounders of both
studies have to be taken into account. Data on smoking habitstegory in the CAIRO2 study cohort. BMI category: A <18.5 kg/
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potential confounder is probably limited, since patients with
significant cardiovascular disease were excluded in both stud-
ies. We did analyse the use of statins in the CAIRO and
CAIRO2 study, since statins may have a beneficial effect on
colorectal cancer prognosis.25 In both studies, no difference
in statin use was observed among the four BMI categories
and in univariate and multivariate analysis the use of statins
was not correlated with OS (data not shown).
A major difference between the two study cohorts is that
targeted therapy, including bevacizumab, was used in the
CAIRO2 study but not in the CAIRO study, due to the fact that
bevacizumab was not yet approved for use at that time. Guiu
et al. showed that ACC patients with a high BMI who received
first line bevacizumab-based therapy had a shorter time to
progression compared to normal weight patients. Further-
more, a high visceral fat area was an independent negative
predictor for survival. This association of body fatness with
outcomes was not observed in patients treated with chemo-
therapy without bevacizumab. The authors explained these
results by a larger volume of distribution of bevacizumab in
obese patients or increased levels of vascular endothelial
growth factor produced by visceral fat, which may be associ-
ated with resistance to bevacizumab.26 This hypothesis is
supported by our results which show a larger survival benefit
for the addition of targeted therapy to chemotherapy in pa-
tients with BMI categories A and B versus patients with BMI
categories C and D. However, this concerns a cross-study
comparison (CAIRO versus CAIRO2), and, therefore, this
should be interpreted with caution.
In conclusion, we found that BMI is an independent prog-
nostic factor for OS in ACC patients receiving chemotherapy.
However, this was not confirmed in a second cohort of ACC
patients with comparable patient characteristics receiving
chemotherapy plus targeted therapy, although a non-signifi-
cant trend towards improved OS with higher BMI was ob-
served. These results may be explained by a decreased
efficacy of bevacizumab in obese patients. Further studies
should confirm this finding.
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